Neuromod and Treble Health Partner to Expand Lenire Access
The partnership makes the bimodal neuromodulation device for tinnitus available through clinics in Philadelphia and Charlotte.
Tag: Lenire
All
Latest
All
Latest
Neuromod Closes €10 Million Financing to Accelerate Commercialization of Lenire
Neuromod Devices Ltd. has secured €10 million in oversubscribed equity financing to expand the availability of its FDA-approved tinnitus treatment device, Lenire.
All
Latest
Neuromod Devices’ Lenire Receives De Novo Approval from FDA
Neuromod Devices' Lenire, a bimodal neuromodulation device, has received De Novo approval from the FDA to treat tinnitus. According to the company, Lenire is the first of its kind to receive FDA approval.
‘Wired’ Article Suggests Apps and Devices to Help with Tinnitus
Described as a “phantom sound generated by the brain” by audiologist Julie Prutsman, tinnitus is a common condition experienced as ringing or buzzing in the ears, often caused by loud noise exposure. While there is no “cure” for tinnitus, there are methods of coping, according to a recent article in “Wired.”
Read More
Neuromod Launches Ótologie Tinnitus Telehealth Service
Medical device company, Neuromod Devices Ltd, announced that it has launched Ótologie, a “specialist telehealth service for tinnitus.” This new service will provide tinnitus patients, throughout the United Kingdom and Europe, with a private care option to avoid waiting lists and give them immediate access to treatment from its telehealth service.
Read More
Neuromod USA Appoints Teri Minard As Director, Gov Sales
Neuromod Devices Ltd, the medical device company which specializes in neuromodulation technologies, has announced the appointment of Teri Minard as Director, Government Sales of its recently established US entity, Neuromod USA Inc.
Read More
Neuromod Appoints Eric Timm as US CEO
Neuromod Devices Ltd, the medical device company which specializes in neuromodulation technologies, has announced the appointment of Eric Timm as Chief Executive Officer of its recently established US entity, Neuromod USA Inc, effective from October 1, 2021.
Read More
Neuromod Appoints Diarmuid Flavin as COO
The Dublin-based tinnitus device maker has hired Diarmuid Flavin as its new COO, after announcing last week the establishment of its US headquarters in Oakbrook, Ill, and the appointment of several well-known hearing industry experts.
Read More
Neuromod Opens USA HQ
Neuromod Devices Ltd, the Irish medical device company specializing in the treatment of tinnitus, has announced the establishment of Neuromod USA Inc, headquartered in Oak Brook, Ill. Three executives with significant experience in the hearing health industry have been appointed to the Neuromod USA leadership team as the organization prepares to enter the US market with its medical device for tinnitus treatment, pending approval from the Food and Drug Administration (FDA).
Read More
Neuromod Appoints Susan Whichard to Board
Whichard has more than 30 years’ experience in the hearing industry, having worked as both a business executive and a practicing healthcare professional, as a clinical audiologist. Her appointment comes as Neuromod plans continued expansion of the availability of Lenire, its tinnitus treatment device across Europe and in the US, pending FDA approval, according to the company’s announcement.
Read More
Survey Shows Many Don’t Receive Tinnitus Treatment
New research from Irish medical device company, Neuromod Devices Ltd, has found that more than three quarters of people suffering from tinnitus in the United Kingdom have never received any treatment for their condition, according to an announcement on the company’s website. The poll also revealed that 67% of UK tinnitus sufferers don’t feel adequately informed about their condition.
Read More
Neuromod Raises $12.4 Million in Series B Funding for Lenire Tinnitus Treatment Device
The investment was led by majority investor Fountain Healthcare Partners, with participation from existing investors Moffett Investment Holdings and Medical Device Resources, with venture-debt provided by Kreos Capital and Silicon Valley Bank.
Read More
Neuromod Publishes Results of Tinnitus Study Utilizing Non-invasive Stimulation Device
The clinical trial was conducted between 2016 and 2019 and was designed to track changes in tinnitus symptom severity. The trial investigated the bimodal neuromodulation approach, using Neuromod’s non-invasive stimulation device that delivers sound to the ears and electrical stimulation to the tongue.
Read More
Neuromod Appoints Rosemarie Tully as COO
In addition to her current responsibilities for corporate development and strategy, Ms Tully will now assume responsibility for all of Neuromod’s operating activities, including manufacturing, supply chain, regulatory, quality, and compliance functions. Ms Tully will continue to report to Dr Ross O’Neill, Chief Executive Officer of Neuromod.
Read More
Neuromod Appoints Florian Elsaesser as Chief Commercial Officer
Elsaesser, a hearing aid industry expert, has worked in the sector for over 12 years in various executive positions for Sivantos and Siemens Audiology.
Read More
Neuromod Closes on $8.75 Million Funding Round
Proceeds from the financing will be used to accelerate ongoing European commercialization of the Company’s Lenire tinnitus treatment device; to scale-up manufacturing capacity to meet anticipated European demand, and to progress the Company’s US regulatory strategy to secure market entry into the United States, according to Neuromod’s announcement.
Read More
Neuromod Names New Members of Senior Leadership Team
Neuromod announces the appointment of Deborah Arthur as Head of Quality and Regulatory Affairs, Suzanne O’Rourke as Director of Quality and Regulatory Affairs, and Cathal Mc Fadden as Director of Operations.
Read More